Tools for drug discovery and disease modeling- the future is upon us

Although technical prowess in screening for drugs has increased dramatically with the development of high content imaging, resonance energy transfer- and intensiometric biosensors, translation into the clinic has stagnated and not all drugs work in all patients. This is likely due to 1) our rudiment...

Full description

Saved in:
Bibliographic Details
Published inMethods (San Diego, Calif.) Vol. 203; pp. 139 - 141
Main Authors Bourque, Kyla, Jones-Tabah, Jace, Hébert, Terence E.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2022
Subjects
Biosensors
Disease modelling
Drug discovery
Induced pluripotent stem cells
Organoids
Primary cells
Primary cells
Disease modelling
Drug discovery
Organoids
Biosensors
Induced pluripotent stem cells
Online AccessGet full text

Cover

More Information
Summary:Although technical prowess in screening for drugs has increased dramatically with the development of high content imaging, resonance energy transfer- and intensiometric biosensors, translation into the clinic has stagnated and not all drugs work in all patients. This is likely due to 1) our rudimentary understanding of disease mechanisms, and 2) our increasing use of generic, cell-based screens which have moved us away from biologically relevant tissues, organs, and patients. Here, we focus on emerging tools to undertake screening and evaluate drug actions in models ranging from heterologous expression systems, primary cells, patient-derived induced pluripotent stem cells and organoids to in vivo models.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1046-2023
1095-9130
DOI:10.1016/j.ymeth.2022.02.003